Neurogene reports Q1 net loss $30.9M; ~90% dosed in Rett gene therapy trial, cash runway to Q1 2028

Neurogene Inc.

2026-Q1 EPS reported -$1.39

Net loss $30.9M for Q1 2026 vs $22.6M in Q1 2025; R&D expenses $25.2M driven by NGN-401 trial and CMC costs.
~90% of participants dosed in Embolden registrational trial; on track to complete dosing in Q2 2026; no HLH at 1E15 vg dose.
Cash, equivalents and short-term investments $243.2M as of March 31, 2026; expected to fund operations through Q1 2028.
Appointed Christy Shafer as Chief Commercial Officer; Christine Mikail added to Board of Directors.
Interim Phase 1/2 data with ≥12 months follow-up for all 10 participants expected mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Neurogene Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end.

Period: the quarter ended March 31, 2026
Net income: Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months end
Result: reported results

Exact text from the filing

Net loss was $30.9 million for the three months ended March 31, 2026, compared to $22.6 million for the three months ended March 31, 2025.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001404644-26-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.